As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
INSIGHTS Study: Investigational Drug Treatment for Patients with Advanced Parkinson's Disease
The purpose of this study is to find out how well the investigational drug known as levodopa carbidopa intestinal gel (LCIG) and its delivery system (through infusion) work to treat nonmotor symptoms (insomnia [inability to sleep], depression, anxiety) in patients with advanced Parkinson's disease compared to optimized medical treatment.
In order to participate you must meet the following criteria:
- Have Parkinson’s disease with non-motor symptoms.
- Are 30 years of age or older.
- Have Parkinson’s disease responsive to levodopa.
You will be excluded from the study if any of the following criteria apply to you:
- Have an unclear diagnosis of Parkinson’s disease (secondary parkinsonism).
- Have undergone neurosurgery for treatment of Parkinson’s disease.
- Have hypersensitivity to levodopa, carbidopa or radiopaque material.
This is a partial list of inclusion and exclusion criteria.